UCB Governance | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

UCB Governance

The Company is administered by a Board of Directors and run by an Executive Committee, whose respective functions and responsibilities are clearly defined in the Corporate Governance Charter.

UCB SA/NV has adopted the 2020 edition of the Belgian Code of Corporate Governance as its reference Code taking into account the specific international aspects of the Company. As part of these rules, UCB SA/NV, as a listed company, has adopted a Corporate Governance Charter and a Code of Conduct, including a Dealing Code.

The Corporate Governance Charter established by the Board of Directors aims at providing a comprehensive and transparent disclosure of the Company’s governance. It defines the system of checks and balances between the shareholders/investors, the Board and the management to shape an efficiently functioning company, ideally geared to produce long-term sustainable value for all the Company’s stakeholders. It will be continuously updated as required.

Articles of Association

Special Reports of the Board

Remuneration Policy

Related Press Releases

Corporate governance charter

Dealing code

Code of conduct


 

Board of Directors

To enhance the overall effectiveness of the Board by ensuring focus, oversight and monitoring of sensitive areas, the Board has created three specialist committees.

the Audit Committee

The Audit Committee assists the Board in its responsibility of monitoring the management of UCB and the UCB Group as a whole.

 

3 members  (67% independent):

  • Jonathan Peacock (Chair & Independent Director)
  • Viviane Monges (Independent Director)
  • Charles-Antoine Janssen (Director)
 
close

the Governance, Remuneration and Nomination Committee (GNCC)

The Governance, Remuneration and Nomination Committee (GNCC) ensures that the appointment and re-election process is organized objectively and professionally and proposes the remuneration policy for non-executive Directors and executive managers. 

 

4 members  (75% independent):

  • Fiona du Monceau (Chair)
  • Stefan Oschmann (Independent Director)
  • Pierre Gurdjian (Independent Director)
  • Kay Davies (Independent Director)
close

the Scientific Committee

The Scientific Committee assists the Board when reviewing the quality of UCB’s R&D science and its competitive standing. It assesses the strategy proposed by UCB’s management in R&D matters and communicates its recommendations to the Board.

 

2 members  (100% independent):

 

  •  Kay Davies (Chair and Independent Director),
  •  Susan Gasser (Independent Director).
 
close

Composition

(Updated: April 2022)

14 Members
8 Independent Directors (57%)
7 Nationalities
5 Women (36%)
4-Year Mandate
Age Limit: 70

 

Stefan Oschmann

Chair of the Board & Independent Director
Member of the GNCC

First appointed in 2021
End of term in 2025

Fiona du Monceau

Vice Chairwoman
Chair of the GNCC

First appointed in 2021
End of term in 2025

Jean-Christophe Tellier

Executive Director

First appointed in 2014
End of term in 2026

Jan Berger

Independent Director

First appointed in 2019
End of term in 2023

Kay Davies

Independent Director
Chair of the Scientific Committee
Member of the GNCC

First appointed in 2014
End of term in 2026

Albrecht De Graeve

Director
 

First appointed in 2010
End of term in 2025

Susan Gasser

Independent Director
Member of the Scientific Committee

First appointed in 2021
End of term in 2025

Pierre Gurdjian

Independent Director
Member of the GNCC

First appointed in 2016
End of term in 2024

Charles-Antoine Janssen

Director
Member of the Audit Committee

First appointed in 2012
End of term in 2024

Cyril Janssen

Director
 

First appointed in 2015
End of term in 2023

Viviane Monges

Independent Director
Member of the Audit Committee

First appointed in 2017
End of term in 2025

Jonathan Peacock

Independent Director
Chair of the Audit Committee

First appointed in 2021
End of term in 2025

Cédric van Rijckevorsel

Director

First appointed in 2014
End of term in 2026

Ulf Wiinberg

Independent Director

First appointed in 2016
End of term in 2024

Honorary directors

  • Karel Boone, Honorary Chair
  • Evelyn du Monceau, Honorary Chair
  • Mark Eyskens, Honorary Chair
  • Georges Jacobs de Hagen, Honorary Chair
  • Daniel Janssen, Honorary Deputy Chair
  • Gerhard Mayr, Honorary Chair
  • Prince Lorenz of Belgium
  • Alan Blinken
  • Alice Dautry
  • Arnoud de Pret
  • Roch Doliveux
  • Peter Fellner
  • Guy Keutgen
  • Jean-Pierre Kinet
  • Tom McKillop
  • Gaëtan van de Werve
  • Jean-Louis Vanherweghem
  • Bridget van Rijckevorsel
  • Norman J. Ornstein
close

Honorary chairmen of the Executive Committee

  • Roch Doliveux
  • Georges Jacobs de Hagen
  • Daniel Janssen
close

 

Executive Committee

We have adapted an organizational structure on four pillars around which we create value for each patient, centered by our focus and integrated across functional teams around different patient populations.

 

Composition

(Updated: February 2022)

9 members
5 nationalities
3 women (33%)
 

 

Jean-Christophe Tellier

Chief Executive Officer &
Chairman of the Executive Committee

Joined UCB in 2011
Appointed CEO in 2015

 

Emmanuel Caeymaex

Executive Vice President
Immunology Solutions & Head of U.S.

Joined UCB in 1994
Appointed in 2015

Sandrine Dufour

Executive Vice President
Chief Financial Officer

Joined UCB in July 2020
Appointed in July 2020

 

Jean Luc Fleurial

Executive Vice President
Chief Human Resources Officer

Joined UCB in 2017
Appointed in 2017

 

Iris Löw-Friedrich

Executive Vice President
Chief Medical Officer

Joined UCB in 2006
Appointed in 2008

 

Kirsten Lund-Jurgensen

Executive Vice President
Supply & Technology Solutions

Joined UCB in 2019
Appointed in 2019

Dhaval Patel

Executive Vice President &
Chief Scientific Officer

Joined UCB in 2017
Appointed in 2017

 

Bill Silbey

 

Executive Vice President &
General Counsel

Joined UCB in 2011
Appointed in 2019

 

Charl van Zyl

 

Executive Vice President
Neurology Solutions & Head of EU / International

Joined UCB in 2017
Appointed in 2017

 

 

Shareholders and Shareholder Meetings

Find out about UCB shareholders, their transparency notifications and our shareholder meetings on the dedicated webpage.